Premium
Central nervous system leukemia and solid tumors of childhood: Treatment with 1,3‐bis (2‐chloroethyl)‐1‐nitrosourea (BCNU)
Author(s) -
Iriarte Pelagio V.,
Hananian Juliet,
Cortner Jean A.
Publication year - 1966
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196609)19:9<1187::aid-cncr2820190902>3.0.co;2-t
Subject(s) - medicine , nitrosourea , leukemia , neuroblastoma , central nervous system , sarcoma , blood cancer , chemotherapy , oncology , pathology , cancer , biology , genetics , cell culture
BCNU (1,3‐bis(2‐chloroethyl)‐1‐nitrosourea) was administered to 6 children with central nervous system leukemia and 8 children with solid tumors. Being lipid soluble, BCNU has the capacity to cross the “blood‐brain barrier,” making it a potentially effective agent for the parenteral treatment of CNS leukemia. Remission of CNS manifestations occurred in 3 of 6 children with CNS leukemia. Temporary regression of tumor was noted in 2 patients with Ewing's sarcoma and in one with neuroblastoma. Thrombocytopenia was a constant feature in all patients. Two died from hemorrhage associated with thrombocytopenia.